Utilizing adenovirus vectors for gene delivery in cancer

Bibliography

• Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 2013;20(2):70-6
   PubMed Web of Science ®Google Scholar
• Choi JW, Lee JS, Kim SW, et al. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 2012;64(8):720-9
   PubMed Web of Science ®Google Scholar
• Singh R, Kostarelos K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol 2009;27(4):220-9
   PubMed Web of Science ®Google Scholar
• Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005;2(5):341-7
   PubMed Web of Science ®Google Scholar
• Kim J, Kim PH, Kim SW, et al. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 2012;33(6):1838-50
   PubMed Web of Science ®Google Scholar
• Cawood R, Hills T, Wong SL, et al. Recombinant viral vaccines for cancer. Trends Mol Med 2012;18(9):564-74
   PubMed Web of Science ®Google Scholar
• Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006;58(8):931-47
   PubMed Web of Science ®Google Scholar
• Kang E, Yun CO. Smart adenovirus nanocomplexes for systemic delivery. Gene Ther Regul 2010;5(1):81-99
   Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30(7):658-70
   PubMed Web of Science ®Google Scholar
• Hallden G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets 2012;16(10):945-58
   PubMed Web of Science ®Google Scholar
• Sachs MD, Rauen KA, Ramamurthy M, et al. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002;60(3):531-6
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shariat SF, Ayala GE, et al. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005;66(2):441-6
   PubMed Web of Science ®Google Scholar
• Kang E, Yun CO. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. BMB Rep 2010;43(12):781-8
   PubMed Web of Science ®Google Scholar
• Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007;7(2):133-9
   PubMed Web of Science ®Google Scholar
• Habib N, Salama H, Abd EL, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002;9(3):254-9
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8(21):1618-26
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62(21):6070-9
   PubMed Web of Science ®Google Scholar
• Perkins SN, Hursting SD, Haines DC, et al. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis 1997;18(5):989-94
   PubMed Web of Science ®Google Scholar
• Bergh J, Norberg T, Sjogren S, et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1(10):1029-34
   PubMed Web of Science ®Google Scholar
• Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12(1):305-13
   PubMed Web of Science ®Google Scholar
• Kim E, Kim JH, Shin HY, et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14(15):1415-28
   PubMed Web of Science ®Google Scholar
• Takakura M, Nakamura M, Kyo S, et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010;17(1):11-19
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Kim PH, Huyn S, et al. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 2010;16(24):6071-82
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61(20):7464-72
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010;18(2):429-34
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318
   PubMed Web of Science ®Google Scholar
• Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2003;5(6):451-62
   PubMed Web of Science ®Google Scholar
• Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16(8):1273-9
   PubMed Web of Science ®Google Scholar
• Han J, Zhao D, Zhong Z, et al. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology 2010;21(10):105106
   PubMed Web of Science ®Google Scholar
• Liu G, Molas M, Grossmann GA, et al. Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation. J Biol Chem 2001;276(37):34379-87
   PubMed Web of Science ®Google Scholar
• Fasbender A, Zabner J, Chillon M, et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997;272(10):6479-89
   PubMed Web of Science ®Google Scholar
• Jiang ZK, Koh SB, Sato M, et al. Engineering polypeptide coatings to augment gene transduction and in vivo stability of adenoviruses. J Control Release 2013;166(1):75-85
   PubMed Web of Science ®Google Scholar
• Wang CH, Chan LW, Johnson RN, et al. The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials 2011;32(35):9536-45
   PubMed Web of Science ®Google Scholar
• Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997;15(2):167-73
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Kang E, Kim S, et al. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. J Control Release 2011;155(2):317-25
   PubMed Web of Science ®Google Scholar
• Wan Y, Han J, Fan G, et al. Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials 2013;34(12):3020-30
   PubMed Web of Science ®Google Scholar
• Wang L, Yao B, Li Q, et al. Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther 2011;22(9):1061-9
   PubMed Web of Science ®Google Scholar
• Kim PH, Kim TI, Yockman JW, et al. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 2010;31(7):1865-74
   PubMed Web of Science ®Google Scholar
• Kim PH, Kim J, Kim TI, et al. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. Biomaterials 2011;32(35):9328-42
   PubMed Web of Science ®Google Scholar
• Kim J, Li Y, Kim SW, et al. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex. Biomaterials 2013;34(19):4622-31
   PubMed Web of Science ®Google Scholar
• Nam HY, Nam K, Lee M, et al. Dendrimer type bio-reducible polymer for efficient gene delivery. J Control Release 2012;160(3):592-600
   PubMed Web of Science ®Google Scholar
• Khandare J, Calderon M, Dagia NM, et al. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem Soc Rev 2012;41(7):2824-48
   PubMed Web of Science ®Google Scholar
• Vetter A, Virdi KS, Espenlaub S, et al. Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. Mol Pharm 2013;10(2):606-18
   PubMed Web of Science ®Google Scholar
• Mok H, Palmer DJ, Ng P, et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11(1):66-79
   PubMed Web of Science ®Google Scholar
• Hofherr SE, Shashkova EV, Weaver EA, et al. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008;16(7):1276-82
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002;13(15):1887-900
   PubMed Web of Science ®Google Scholar
• Wang C, Pham PT. Polymers for viral gene delivery. Expert Opin Drug Deliv 2008;5(4):385-401
   PubMed Web of Science ®Google Scholar
• Niu G, Xiong Z, Cheng Z, et al. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol 2007;9(3):126-34
   PubMed Web of Science ®Google Scholar
• Jung Y, Park HJ, Kim PH, et al. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 2007;123(2):164-71
   PubMed Web of Science ®Google Scholar
• Kim PH, Sohn JH, Choi JW, et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 2011;32(9):2314-26
   PubMed Web of Science ®Google Scholar
• Kim K, Choi JW, Ma K, et al. Nanoisland-based random activation of fluorescence for visualizing endocytotic internalization of adenovirus. Small 2010;6(12):1293-9
   PubMed Web of Science ®Google Scholar
• Saini V, Martyshkin DV, Mirov SB, et al. An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Small 2008;4(2):262-9
   PubMed Web of Science ®Google Scholar
• Li F, Zhang ZP, Peng J, et al. Imaging viral behavior in Mammalian cells with self-assembled capsid-quantum-dot hybrid particles. Small 2009;5(6):718-26
   PubMed Web of Science ®Google Scholar
• Raty JK, Liimatainen T, Wirth T, et al. Magnetic resonance imaging of viral particle biodistribution in vivo. Gene Ther 2006;13(20):1440-6
   PubMed Web of Science ®Google Scholar
• O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999;10(8):1349-58
   PubMed Web of Science ®Google Scholar
• Fisher KD, Seymour LW. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev 2010;62(2):240-5
   PubMed Web of Science ®Google Scholar
• Kopecek J, Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010;62(2):122-49
   PubMed Web of Science ®Google Scholar
• Subr V, Kostka L, Selby-Milic T, et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release 2009;135(2):152-8
   PubMed Web of Science ®Google Scholar
• Shan L, Cui S, Du C, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33(1):146-62
   PubMed Web of Science ®Google Scholar
• Fuchs IB, Landt S, Bueler H, et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat 2003;82(1):23-8
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Pechar M, Carlisle RC, et al. Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res 2010;27(11):2274-82
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Kang E, Choi JW, et al. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. J Control Release 2013;169(3):257-65
   PubMed Web of Science ®Google Scholar
• Yao X, Yoshioka Y, Morishige T, et al. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther 2011;19(9):1619-25
   PubMed Web of Science ®Google Scholar
• Morrison J, Briggs SS, Green NK, et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther 2009;20(3):239-51
   PubMed Web of Science ®Google Scholar
• Hiemstra C, Zhong Z, Van Tomme SR, et al. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels. J Control Release 2007;119(3):320-7
   PubMed Web of Science ®Google Scholar
• He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 2008;127(3):189-207
   PubMed Web of Science ®Google Scholar
• Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012;37(1):106-26
   PubMed Web of Science ®Google Scholar
• Hatefi A, Cappello J, Ghandehari H. Adenoviral gene delivery to solid tumors by recombinant silk-elastinlike protein polymers. Pharm Res 2007;24(4):773-9
   PubMed Web of Science ®Google Scholar
• Greish K, Frandsen J, Scharff S, et al. Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J Gene Med 2010;12(7):572-9
   PubMed Web of Science ®Google Scholar
• Choi JW, Kang E, Kwon OJ, et al. Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy. Gene Ther 2013;20(9):880-92
   PubMed Web of Science ®Google Scholar